**RULES:**

**Change to:**

Platelets

**From (in this order below):**

Platelet count

Platelets:

Platelet (PLTs)

**Change to:**

>=

**From (in this order below):**

>

greater than or equal to

**Change to:**

mcL

**From (in this order below):**

cell/mm^3

/m^3

/mm�

/microliters

**Change to:**

,000/mcL

**From (in this order below):**

x10^9/L

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**TEMPLATE:**

**Template for: Platelets**

**English:**

“Platelets >=

VARIABLE1 = {“100,000”,“75,000”, OTHER}

/mcL

VARIABLE2 =

{

EMPTY,

“obtained =<

VARIABLE3 = {“21”, “14”, “30”, OTHER}

days prior to registration

VARIABLE4 =

{

EMPTY,

“(transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)”

}

”

}

”

**Code:**

“(C51951 >=

VARIABLE1 = {“100,000”, “75,000”, OTHER}

/uL)

VARIABLE2 =

{

EMPTY,

“AND ((C25646 =<

VARIABLE3 = {“21”, “14”, “30”, OTHER}

d) AND (C63325=C93535))

VARIABLE4 =

{

EMPTY,

“AND (C15366 = NO)”

}

”

}

”

**EXAMPLE English:**

Platelets >= 100,000/mcL obtained =< 21 days prior to registration (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

**EXAMPLE Code:**

(C51951 >= 100,000/uL) AND ((C25646 =<21d) AND (C63325=C93535)) AND (C15366 = NO)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**ORIGINAL DATA:**

Platelets (PLT) >= 100,000/mcL

36.0

Platelets >= 100,000/mcL

102.0

Platelets >= 100,000/mcl

360.0

Platelets >= 100,000/mcL

276.0

Platelets >= 100,000/mcl

162.0

Platelets >= 100,000/mcL

40.0

Platelets >= 100,000/mcL

107.0

Platelets >= 100,000/mcl

52.0

Platelets >= 100,000/mcL

55.0

Platelets >= 100,000/mcL

165.0

Platelets >= 100,000/mcL

42.0

Platelets >= 100,000/mcL

36.0

Platelets >= 100,000/mcL

140.0

Platelets >= 100,000/mcL

80.0

Platelets >= 100,000/mcL

68.0

Platelets >= 75,000/mcL

42.0

Platelets >= 100,000/mcL

73.0

Platelets >= 100,000/mcL

80.0

Platelets >= 100,000/mcL

70.0

Platelets >= 100,000/mcL

72.0

Platelets >= 100,000/mcL (without transfusion)

12.0

Platelets >= 100,000/mcL

68.0

Platelets greater than or equal to 100,000/mcl

540.0

Platelets >= 50,000/mcL

54.0

Platelets >= 100,000/mcL

32.0

Platelets >= 100,000/mcL

100.0

Platelets >= 100,000/mcL

24.0

Platelets >= 100,000/mcL

35.0

Platelets >= 100,000/mcL

230.0

Platelets >= 100,000/mcL

40.0

Platelets >= 100,000/mcL

57.0

Platelets >= 50,000 cells/mcL (50 x 10^9/L)

52.0

Platelets >= 100,000/mcL

90.0

Platelets >= 100,000/mcL

36.0

Platelets >= 100,000/mcL

23.0

Platelets >= 50,000/mcL or recovery to the baseline count

80.0

Platelets >= 75,000/mcL

135.0

Platelets >= 100,000/mcL

37.0

Platelets >= 150,000/mcL

66.0

Platelets >= 50,000/mcL

12.0

Platelets >= 100,000/mcL

42.0

Platelets >= 100,000/mcL

209.0

Platelets >= 100,000/mcL

30.0

Platelets >= 100,000/mcL

75.0

Platelets >= 100,000/mcL (not requiring platelet transfusions)

50.0

Platelets >= 100,000/mcL

30.0

Platelets >= 100,000/mcL

549.0

Platelets >= 100,000/mcL

680.0

Platelets >= 100,000/mcL

46.0

Platelets >= 100,000/mcL

45.0

Platelets >= 100,000/mcL

82.0

Platelets >= 100,000/mcL

126.0

Platelets >= 100,000/mcL

150.0

Platelets >= 100,000/mcL

50.0

Platelets >= 75,000/mcL

46.0

Platelets >= 100,000/mcL

15.0

Platelets >= 100,000/mcL

46.0

Platelets >= 50,000/mcL

36.0

Platelets >= 100,000/mcL

90.0

Platelets >= 100,000/mcL

45.0

Platelets >= 75,000/mcL, unless due to marrow involvement by lymphoma in which case a platelet count of >= 30,000/mcL will be used

50.0

Platelets >= 100,000/mcL

46.0

Platelets > 50,000/mcL

60.0

Within 2 weeks prior to initiation of study treatment: Platelets >= 100,000/mcL

70.0

Platelets >= 100,000/mcL (without transfusion within 2 weeks prior to cycle 1, day 1)

29.0

Platelets >= 100,000/mcL

51.0

Platelets >= 100,000/mcL

150.0

Platelets >= 100,000/mcL

48.0

Platelets >= 100,000/mcL

20.0

Platelets >= 75,000/mcl

84.0

Platelets >= 100,000/mcL

60.0

Platelets >= 100,000/mcL

38.0

Platelets >= 100,000/mcL

70.0

Platelets >= 100,000/mcL

24.0

Platelets >= 100,000/mcL

35.0

Platelets >= 100,000/mcL (not requiring platelet transfusions)

24.0

Platelets >= 100,000/mcL

28.0

Platelets >= 100,000/mcL

148.0

Platelets >= 100,000/mcL

72.0

Platelets >= 75,000/mcL (>= 50,000 for patients with hematologic malignancies)

40.0

Platelets >= 150,000/mcL

60.0

Platelets >= 100,000/mcL

180.0

Platelets >= 100,000/mcL

40.0

Platelets >= 100,000/mcL

22.0

Platelets >= 100,000/mcL

70.0

Platelets >= 100,000/mcL

47.0

Platelets >= 100,000/mcL

35.0

Platelets >= 100,000/mcL

78.0

Platelet count: >= 50,000/mm^3, transfusion independent (no platelet transfusions within 1 week)

62.0

Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

77.0

For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

154.0

Platelets >= 100,000/mm^3 transfusion independent (no platelet transfusion one week prior to enrollment)

40.0

Platelet count >= 75,000 and transfusion independent

28.0

For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

148.0

Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

484.0

\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

81.0

Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

67.0

For patients with solid tumors without known bone marrow involvement: \* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\* Hemoglobin >= 8.0 g/dl at baseline (may receive packed red blood cell [PRBC] transfusions)

65.0

Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

36.0

Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvement

146.0

For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\* Hemoglobin >= 8.0 g/dl at baseline (may receive red blood cell [RBC] transfusions)

51.0

For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

49.0

For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

98.0

For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

49.0

For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

49.0

For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

144.0

For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 7 days prior to enrollment \* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)

49.0

GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:\* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment

1500.0

Platelet count >= 100,000/ul

729.0

Platelet count > 75,000/uL

253.0

Platelet count >= 100,000/uL

100.0

Platelet count >= 100,000/uL

74.0

Platelet count >= 100,000/uL (transfusion independent)

275.0

Platelet count >= 75,000/uL (transfusion independent)

74.0

CD4 count >= 50 cells/ul

70.0

Platelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility

340.0

Platelet count >= 100,000/uL, obtained within 4 weeks prior to randomization

300.0

Platelet count >= 100,000/uL

400.0

Platelets >= 75,000 cells /uL (unsupported, defined as no platelet transfusion within 7 days)

110.0

INCLUSION CRITERIA FOR STRATUM C: Platelets >= 75,000 cells/uL (unsupported, defined as no platelet transfusion within 7 days)

110.0

Platelet count >= 50,000/uL

44.0

Absolute CD4 count > 200 cells/uL

46.0

Platelet count >= 75,000/uL

337.0

CD4+ T-cell count >= 100 cells/uL

60.0

Platelet count >= 100,000/uL (transfusion independent)

45.0

Platelets >= 100,000/uL (untransfused)

400.0

Platelets >= 100,000 cells/uL (75 x 10^9 L); and,

90.0

Platelets >= 100,000/ul

97.0

Platelets >= 100,000/uL

72.0

Platelets >= 100,000/ul

104.0

TUMOR BIOPSY SEQUENCING: Platelets >= 100,000/uL (mcL)

700.0

TREATMENT: Platelets >= 100,000/uL (mcL)

700.0

Platelets >= 100,000/ul (unsupported)

52.0

Platelets >= 90 x 10^3/uL

92.0

Platelets >= 100,000/uL

23.0

Platelets >= 100,000/ul

280.0

Platelets >= 100,000/ul

450.0

Platelets >= 100,000/ul

96.0

Platelets >= 100,000/uL

58.0

Platelets >= 100,000/uL

35.0

Platelets > 100,000/uL

188.0

Platelets >= 100,000/uL

33.0

Platelets > 100,000/uL

32.0

Platelets >= 100 x 10^3/uL

714.0

Platelets >= 100,000/uL

40.0

Platelets >= 100,000/uL

30.0

Platelets >= 100,000/ul

50.0

Platelet count >= 100,000/mm�

700.0

Platelet (PLTs) count >= 100,000/mm^3 obtained =< 21 days prior to registration

360.0

Platelet count >= 100,000 cells/mcL

155.0

Peripheral platelet count (PLT) >= 75,000/mm^3

48.0

Platelet count >= 100,000/mm^3

1120.0

Platelet count > 100,000

224.0

Platelet count >= 100,000/mL within 28 days prior to registration

1900.0

STEP I: Untransfused platelet count >= 75,000 cells/mm^3 (obtained within 28 days prior to randomization)

1080.0

Platelet count < 100 x 10^9/L

45.0

Platelet count > 100,000/mm^3

2060.0

Platelet count >= 50 x 10^9/L

97.0

Platelet count >= 75,000/mm^3 within 90 days prior to randomization

150.0

Platelet count >= 100,000/mm^3

34.0

Platelet count >= 100,000 mcl obtained within 28 days prior to sub-study registration

10000.0

Platelet count >= 100 x 10^9/L

250.0

Platelet count >= 100 x 10^9/L measured within 28 days prior to randomization

1500.0

Platelet count >= 100,000/mm^3

20.0

Platelet count >= 100,000/mcL

600.0

Patients on Part C with acute lymphoblastic leukemia: platelet count >= 20,000/mm^3 (may receive platelet transfusions); these patients must not be known to be refractory to red cell or platelet transfusion

148.0

Platelet count > 50,000/mm^3

125.0

Platelet count >= 75,000/mm^3

30.0

Platelet count >= 100,000/mm^3

420.0

Within 6 weeks prior to randomization: Platelet count must be >= 100,000/mm^3

990.0

Platelet count >= 100,000/mm^3

195.0

Re-registration: platelet count >= 100,000/mm^3

195.0

Within 14 days of registration: Platelet count >= 75,000/mm^3

110.0

Platelet count >= 100,000/mm^3

69.0

Platelet count >= 100,000/mm^3

130.0

Platelet count >= 100,000/mm^3

45.0

Platelet count >= 75,000/mcL; must be obtained within 28 days prior to registration

180.0

Platelet count >= 100,000/ mL within 21 days prior to registration

333.0

Platelet count >= 100,000/mm^3

137.0

CLINICAL/LABORATORY CRITERIA: Platelet count >= 100,000/mcL; these results must be obtained within 28 days prior to registration

53.0

Platelet count must be >= 100,000/mm^3 within 28 days before randomization

348.0

Platelet count >= 100,000/mm^3, within 4 weeks of randomization

766.0

Platelet count >= 100,000/mm^3

124.0

Platelet count >= 100,000 mm^3; platelets >= 75,000 required for patients who received cycle 1 of mFOLFOX6 prior to registration

700.0

Platelet count < 100 x 10^9/L

98.0

Platelet count >= 75,000/mm^3

324.0

Platelets >= 100,000 cells/mm^3

285.0

Platelets >= 100,000 cells/mm^3

37.0

Platelets >= 70,000 cells/mm^3, within 21 days prior to study entry

143.0

Platelets >= 60,000 cells/mm^3; obtained within 14 days prior to study entry

368.0

Platelets >= 100,000 cells/mm^3

252.0

Platelets >= 100,000 cells/mm^3

660.0

Platelets >= 100,000 cells/mm^3

234.0

Platelets >= 100,000 cells/mm^3 obtained within 30 days prior to registration

330.0

Platelets >= 100,000 cells/mm^3 within 14 days prior to study registration

440.0

Platelets >= 100,000 cells/mm^3, within 21 days prior to registration

924.0

Platelets >= 100,000 cells/mm^3

182.0

Platelets >= 100,000 cells/mm^3

606.0

Platelets >= 50,000 cells/mm^3

360.0

Platelets >= 50,000 cells/mm^3

186.0

Platelets >= 100,000 cells/mm^3

120.0

Platelets >= 100,000/mm^3, equivalent to CTCAE v 3.0 grade 0-1

164.0

Platelets >= 100,000/mm^3

545.0

Within 60 days prior to registration on study: Platelets >= 100,000/mm^3

2580.0

Platelets >= 100,000/mm^3

130.0

Platelets >= 100,000/mm^3

110.0

Platelets >= 100,000/mm^3

52.0

Platelets: >= 75,000/mm^3 within 90 days before enrollment

5058.0

Platelets >= 50,000 /mm^3

84.0

Platelets >= 100,000/mm^3

44.0

Platelets >= 30,000/mm^3

NONE

Platelets > 100,000 mm^3, must be obtained within 8 weeks prior to screening for protocol therapy

562.0

Platelets: >= 100,000/mm^3

56.0

Platelets >= 100,000/mm^3

60.0

Platelets >= 100,000/mm^3

126.0

Platelets >= 100,000/mm^3 within 4 weeks prior to randomization

345.0

Platelets >= 100,000/mm^3

36.0

Platelets >= 100,000/mm^3

24.0

Platelets: >= 100,000 / mm^3

56.0

Platelets >= 100,000 cell/mm^3

612.0

Platelets >= 100,000/mcL assessed within seven (7) days prior to the start of therapy

30.0

REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Platelets >= 100,000/mcl

162.0

Obtained within 30 days of registration: Platelets >= 75,000/mcL or >= 50,000/mcL with documented bone marrow involvement

24.0

Platelets >= 100,000/mcL within 28 days prior to registration

491.0

Obtained =< 7 days prior to registration: Platelets (PLT) >= 100,000/mm^3

102.0

Platelets >= 100,000/L (unsupported), within 14 days of registration and within 7 days of the start of treatment

180.0

Platelets >= 75,000/mcL (75 x 10^9/L) obtained within 2 weeks prior to registration

189.0

Platelets >= 50,000/mcl within 28 days prior to registration

44.0

Registration Step 3 � Maintenance: Patients must have adequate marrow function as evidenced by platelets >= 75,000/mcl within 28 days prior to registration

44.0

Obtained within 28 days prior to registration: Platelets >= 75,000/mcL

223.0

Within 14 days prior to registration: Platelets >= 100,000/mcL

143.0

Platelets greater than or equal to 100,000/mcl, within 14 days prior to registration

147.0

Obtained within 28 days prior to registration: Platelets >= 50,000/mcl

77.0

Platelets >= 100 x 10^9/L within 14 days prior to registration.

186.0

Within 28 days prior to registration: Platelets >= 75,000/mcL

707.0

Within 14 days prior to registration: Platelets >= 100,000/mcl

488.0

Within 28 days prior to administration of study treatment: Platelets >= 100,000/mcL

90.0

Within less than or equal to 14 days prior to registration: Platelets >= 100 x 10^9/L

40.0

Within 28 days prior to administration of therapy: Platelets >= 100,000/mcL

132.0

Platelets >= 100,000/mcL, obtained within 28 days prior to step 2 registration

1000.0

Platelets >= 100,000/mcL within 28 days prior to registration

64.0

Platelets >= 75,000/mcL within 28 days prior to registration

150.0

Platelets >= 100,000/mcL within 28 days prior to registration

94.0

Platelets >= 100 x 10^9/L

72.0

Platelets >= 100 x 10^9/L

30.0

Platelets >= 100 x 10^9/L

40.0

Platelets >= 100 x 10^9/L, within 2 weeks of the first dose of study treatment

18.0

Platelets >= 75 x 10^9/L

68.0

Platelets >= 100 x 10^9/L

130.0

Platelets >= 100 x 10^9/L

35.0

Platelets >= 100 x 10^9/L

18.0

Platelets (Plt) > 100

23.0

Platelets >= 100,000/microliters

37.0

Platelets >= 100 x 10^9/L

36.0

Platelets >= 100 x 10^9/L

64.0

Platelets >= 100 x 10^9/L (transfusion dependent)

25.0

Platelets >= 75 x 10^9/L

68.0

Platelets >= 100,000 x 10^9 /L

21.0

Platelets >= 75 x 10^9/L within 30 days of day 1 of study

27.0